The effect of chemotherapy on endothelial function and microcirculation in patients with gastric cancer

Objective. To evaluate and study the dynamics of endothelial dysfunction instrumental indicators, vascular wall stiffness and microcirculation state in patients with gastric cancer (adenocarcinoma) before and after chemotherapy; compare it with the results obtained from healthy volunteers and patients with cardio-vascular diseases.
Materials and Methods. The study included 65 people: 25 healthy volunteers, 15 patients with known cardio-vascular diseases (CVD) and 25 patients with histologically confirmed gastric cancer (adenocarcinoma) stage 2—4 who underwent surgical treatment followed by chemotherapy according to the FOLFOX, XELOX, and XP regimes. For non-invasive assessment of the vascular wall’s state of large vessels and microcirculation, all patients in the main group underwent computer nailfold capillaroscopy and finger photoplethysmography before chemotherapy and within a month after the completion of the last course. For healthy volunteers and patients with CVD, the above studies were performed once during the examination.
Results. The data obtained indicate a significant increase in the reflection index of small muscle arteries (RI) and the stiffness index of large conducting arteries (aSI) during chemotherapy. In cancer patients, even before the treatment, endothelial dysfunction was detected, which significantly worsened after treatment (occlusion index (IO) before and after chemotherapy 1.7 (1.38; 1.9) vs. 1.3 (1.2; 1.5), p<0.0002, respectively). Significant differences in the compared indices in cancer patients and CVD group were revealed only after chemotherapy. Significant structural and functional disorders of capillaries were noted in the studied groups, which also worsened during chemotherapy in the main group (density of the capillary network at rest 43.23cap/mm2 vs. 42.19cap/mm2, p <0.01, respectively; density of the capillary network after the reactive hyperemia test 46.77cap/mm2 vs. 44.11cap/mm2, p<0,02, respectively).
Conclusion. In this study, for the first time, the dynamics of endothelial dysfunction indicators, vascular wall stiffness and microcirculation state in patients with gastric cancer were studied, and a reliable increasing of these changes was proved during chemotherapy. The results indicate the need for a further search for accurate and effective methods of identifying early signs of close and distant vasculotoxicity, the development of individual prevention programs in order to significantly reduce the risk of cardiovascular events during and after chemotherapy.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. International Journal of Cancer. 2015;136(5):E359–86. DOI: 10.1002/ijc.29210

2. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (incidence and mortality). -M.: MNIOI them. P. A. Herzen-branch of FSBI ‘NMITS radiology’ MH of Russia;2018. 250 p. In Russian ISBN 978-5-85502-243-8

3. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V et al. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. Journal of Clinical Oncology. 2010;28(9):1547–53. DOI: 10.1200/JCO.2009.25.4706

4. Al-Batran S-E, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R et al. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology. 2008;26(9):1435–42. DOI: 10.1200/JCO.2007.13.9378

5. Kang Y-K, Kang W-K, Shin D-B, Chen J, Xiong J, Wang J et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology. 2009;20(4):666–73. DOI: 10.1093/annonc/mdn717

6. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(36):2768– 801. DOI: 10.1093/eurheartj/ehw211

7. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2012;23(Suppl 7):vii155-166. DOI: 10.1093/annonc/mds293

8. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119–31. DOI: 10.1056/NEJMoa1707914

9. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J et al. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease). Circulation. 2006;114(25):2850–70. DOI: 10.1161/CIRCULATIONAHA.106.655688

10. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal. 2006;27(21):2588–605. DOI: 10.1093/eurheartj/ehl254

11. Gates PE, Strain WD, Shore AC. Human endothelial function and microvascular ageing: Ageing microvessels. Experimental Physiology. 2009;94(3):311–6. DOI: 10.1113/expphysiol.2008.043349

12. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension: A Disease of the Microcirculation? Hypertension. 2006;48(6):1012–7. DOI: 10.1161/01.HYP.0000249510.20326.72

13. Brana I, Tabernero J. Cardiotoxicity. Annals of Oncology. 2010;21(Suppl 7):vii173–9. DOI: 10.1093/annonc/mdq295

14. Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WTA, de Vries EGE, Sleijfer DT. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treatment Reviews. 2000;26(6):429–47. DOI: 10.1053/ctrv.2000.0175

15. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos M-A et al. Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications. Cancer Treatment Reviews. 2012;38(5):473–83. DOI: 10.1016/j.ctrv.2011.09.002

16. de Vos FYFL, Nuver J, Willemse PHB, van der Zee AGJ, Messerschmidt J, Burgerhof JGM et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage. European Journal of Cancer. 2004;40(5):696–700. DOI: 10.1016/j.ejca.2003.11.026

17. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. Journal of the American College of Cardiology. 2004;44(11):2137–41. DOI: 10.1016/j.jacc.2004.08.062

18. Cameron AC, Touyz RM, Lang NN. Vascular Complications of Cancer Chemotherapy. Canadian Journal of Cardiology. 2016;32(7):852– 62. DOI: 10.1016/j.cjca.2015.12.023

19. Celermajer DS. Testing endothelial function using ultrasound. Journal of Cardiovascular Pharmacology. 1998;32(Suppl 3):S29-32. PMID: 9883744

20. Nathan C, Xie Q. Nitric oxide synthases: Roles, tolls, and controls. Cell. 1994;78(6):915–8. DOI: 10.1016/0092-8674(94)90266-6

21. Pak L.A., Manambaeva Z.A., Noso Y. Endothelial dysfunction in patients with rectal cancer and its impact on the hemostatic system and the risk of thrombotic complications. Medicine (Almaty). 2016;5(167):35–40. In Russian

22. Lévy BI. Microvascular Plasticity and Experimental Heart Failure. Hypertension. 2006;47(5):827–9. DOI: 10.1161/01.HYP.0000215283.53943.39

23. Lerman A, Zeiher AM. Endothelial Function: Cardiac Events. Circulation. 2005;111(3):363–8. DOI: 10.1161/01.CIR.0000153339.27064.14

24. Ferrara LA, Guida L, Ferrara F, De Luca G, Staiano L, Celentano A et al. Cardiac structure and function and arterial circulation in hypertensive patients with and without metabolic syndrome. Journal of Human Hypertension. 2007;21(9):729–35. DOI: 10.1038/sj.jhh.1002222

25. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M et al. Digital Assessment of Endothelial Function and Ischemic Heart Disease in Women. Journal of the American College of Cardiology. 2010;55(16):1688–96. DOI: 10.1016/j.jacc.2009.10.073

26. Dubiel M, Królczyk J, Gąsowski J, Grodzicki T. Skin microcirculation and echocardiographic and biochemical indices of left ventricular dysfunction in non-diabetic patients with heart failure. Cardiology Journal. 2011;18(3):270–6. PMID: 21660916

27. Lockhart CJ, Hamilton PK, Quinn CE, McVeigh GE. End-organ dysfunction and cardiovascular outcomes: the role of the microcirculation. Clinical Science. 2009;116(3):175–90. DOI: 10.1042/CS20080069